Regorafenib-related myocardial injury during atrial fibrillation

Fu Chih Hsiao, Chun Nan Yeh, Pao Hsien Chu*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

3 Scopus citations

Abstract

Multikinase inhibitors with an anti-vascular endothelial growth factor effect have been reported to increase the risk of myocardial infarction or ischemia. We have presented the case of a 72-year-old male who had a metastatic gastrointestinal stromal tumor for which he received targeted therapy and who was admitted to our hospital for recurrent episodes of myocardial injury during atrial fibrillation. Coronary angiography showed insignificant coronary artery stenosis.We also reviewed the incidence of cardiovascular events in patients receiving regorafenib, and the current understanding of the mechanism of targeted therapy-induced myocardial ischemia/infarction.

Original languageEnglish
Pages (from-to)243-246
Number of pages4
JournalActa Cardiologica Sinica
Volume32
Issue number2
DOIs
StatePublished - 03 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016, Republic of China Society of Cardiology. All rights reserved.

Keywords

  • Multikinase inhibitor
  • Myocardial infarction
  • Myocardial ischemia
  • Vascular endothelial growth factor

Fingerprint

Dive into the research topics of 'Regorafenib-related myocardial injury during atrial fibrillation'. Together they form a unique fingerprint.

Cite this